TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:22
CERUS CORP ( CERS ) https://www.cerus.com
1.66USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-26.55%
CERS
SPY
32.66%
-75.52%
CERS
SPY
108.59%
-61.21%
CERS
SPY
302.52%
-73.40%
CERS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
307.80
246.77
0.94
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-15.60
1.75
5.67
-8.45
0.00
-21.15
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2.09
56.93
-6.65
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.552
-14.28
-11.88
1.15
Other Earnings and Cash Flow Stats:
CERUS CORP ( CERS ) Net Income TTM ($MM) is -19.72
CERUS CORP ( CERS ) Operating Income TTM ($MM) is -18.37
CERUS CORP ( CERS ) Owners' Earnings Annual ($MM) is 0.00
CERUS CORP ( CERS ) Current Price to Owners' Earnings ratio is 0.00
CERUS CORP ( CERS ) EBITDA TTM ($MM) is -16.14
CERUS CORP ( CERS ) EBITDA Margin is -6.65%
Capital Allocation:
CERUS CORP ( CERS ) has paid 0.00 dividends per share and bought back -4.486 million shares in the past 12 months
CERUS CORP ( CERS ) has reduced its debt by 82.657 million USD in the last 12 months
Capital Structure:
CERUS CORP ( CERS ) Interest-bearing Debt ($MM) as of last quarter is 14
CERUS CORP ( CERS ) Annual Working Capital Investments ($MM) are -12
CERUS CORP ( CERS ) Book Value ($MM) as of last quarter is 54
CERUS CORP ( CERS ) Debt/Capital as of last quarter is 27%
Other Balance Sheet Stats:
CERUS CORP ( CERS ) has 21 million in cash on hand as of last quarter
CERUS CORP ( CERS ) has 54 million of liabilities due within 12 months, and long term debt 83 as of last quarter
CERUS CORP ( CERS ) has 185 common shares outstanding as of last quarter
CERUS CORP ( CERS ) has 0 million USD of preferred stock value
Academic Scores:
CERUS CORP ( CERS ) Altman Z-Score is -5.25 as of last quarter
CERUS CORP ( CERS ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
CERUS CORP ( CERS ) largest shareholder is owning shares at 0.00 ($MM) value
Jensen Chrystal(an insider) Sold 16667 shares of CERUS CORP ( CERS ) for the amount of $28500.57 on 2024-12-16
3.27% of CERUS CORP ( CERS ) is held by insiders, and 75.06% is held by institutions
CERUS CORP ( CERS ) went public on 1997-01-30
Other CERUS CORP ( CERS ) financial metrics:
FCF:-26.93
Unlevered Free Cash Flow:0.00
EPS:-0.06
Operating Margin:-2.09
Gross Profit Margin:56.93
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-21.94
Beta:1.15
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About CERUS CORP ( CERS ) :
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.